Emerging Therapies: Nucala (US) is a three-wave syndicated detailed expanded analysis that specifically tracks the introduction of Nucala, the first IL-5 inhibitor approved to treat eosinophilic asthma. This series is based on primary research data collected at one month, six months, and one year post-commercial availability of Nucala. Along with awareness and sources of familiarity, the reports assess U.S. pulmonologists’ and allergists’ trial, adoption, and use of Nucala, including anticipated future trends. The analysis also provides information on product perception, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, GlaxoSmithKline’s promotional efforts, and benchmarking against previously launched immune biologic therapies. This module also includes an overview and pipeline analysis of emerging asthma therapies from early to late phase clinical development as well as detailed profiles, expert insights, and commercial outlook for select therapies in late-phase commercial development.

Table of contents

  • Asthma - Emerging Therapies - Nucala Launch Tracking (US) Wave 2
    • Key Findings
      • Benchmarking Nucala's Launch Success vs. Launch Success of the Competition
        • Prescriber and Nonprescriber Profiles
          • Differences Between Nucala Prescriber and Nonprescriber Profiles
        • Nucala Awareness and Perceptions
          • Unaided and Aided Awareness of Nucala
            • Changes Made to Asthma Treatment
            • Asthma Treatments Available (Unaided)
            • Familiarity with Nucala Among Pulmonologists and Allergists
            • Awareness of Approved Indications for Nucala
            • Awareness of Approved Patients for Nucala
            • Physician Quotes on Unaided and Aided Awareness of Nucala
          • Familiarity with Nucala
            • Level of Familiarity with Nucala Among Pulmonologists and Allergists
          • Sources of Familiarity with Nucala
            • Ways Physicians Become Familiar with Nucala
            • Physician Quotes on Sources of Familiarity with Nucala
          • Initial Reaction to and Interest in Nucala
            • Nucala Product Profile
            • Reactions to Nucala
            • Awareness Among Pulmonologists of Information on Nucala's Product Profile
            • Nucala Features that Pulmonologists Were Not Aware of in Nucala Product Profile
            • Awareness Among Allergists of Information in Nucala's Product Profile
            • Nucala Features that Allergists Were Not Aware of in Nucala's Product Profile
            • Level of Interest in Nucala
            • Physician Quotes on Initial Reaction to and Interest in Nucala
          • Impressions of Nucala
            • Nucala’s Level of Uniqueness
            • Unaided Advantages of Nucala
            • Unaided Disadvantages of Nucala
            • Balance Between Risks and Benefits of Nucala
            • Physician Quotes on Impressions of Nucala
          • Prescriber and Nonprescriber Profiles
            • Nucala Prescriber and Nonprescriber Profiles
        • Nucala Trial and Use
          • Willingness to Prescribe Nucala
            • Physician Quotes on Willingness to Prescribe Nucala
          • Number of Patients Currently Receiving Nucala
            • Asthma Patients Prescribed Nucala
            • Prescriber vs. Nonprescriber
            • Nucala Patients by Asthma Severity Classifications
            • Current and Discontinued Nucala Patients
            • Reasons for Discontinuing Nucala
            • Nucala Treatment: Effect on Other Treatment Regimens
            • Products Maintained in Nucala Patients
            • Products Displaced by Nucala
            • Physician Prescribing of Additional Therapies with Nucala
            • Patient Inquiries to Allergists about Nucala
            • Patient Inquiries to Pulmonologists about Nucala
            • Patients Specifically Requesting Nucala
            • Physician Quotes on Current Use of Nucala
          • Reasons for Not Yet Prescribing Nucala
            • Reasons for Not Yet Prescribing Nucala Among Pulmonologists
            • Reasons for Not Yet Prescribing Nucala Among Allergists
            • Physician Quotes on Reasons for Not Prescribing Nucala
          • Anticipated Nucala Use
            • Anticipated Time Until First Nucala Prescription
            • Patients to Be Initiated on Nucala Within One Month
            • Patients Most Likely to Be Initially Prescribed Nucala
            • Likely Candidates for Nucala, by Asthma Severity
            • Physician Quotes on Anticipated Nucala Use
          • Nucala Performance on Key Attributes
            • Overall Satisfaction with Nucala
            • Reasons for High Overall Satisfaction with Nucala
            • Experience with Nucala's Managed Care Approval Process
            • Satisfaction with Nucala Metrics Among Pulmonologists
            • Satisfaction with Nucala Metrics Among Allergists
            • Satisfaction with Nucala Metrics Among Pulmonologists
            • Satisfaction with Nucala Metrics Among Allergists
            • Impact of Nucala Safety Concerns Among Pulmonologists
            • Impact of Nucala Safety Concerns Among Allergists
            • Impact of Nucala Safety Concerns
            • Physician Quotes on Nucala Performance on Key Attributes
        • Effectiveness of Face-to-Face Detailing for Nucala
          • Nucala Sales Representative Frequency and Reach
            • Nucala Representative Visits to Pulmonologists and Allergists
            • Materials Used by Nucala Representatives
            • Materials and Samples Provided
            • Physicians' Interest in Receiving Nucala Samples from Representatives
            • Utilization of Nucala Samples by Pulmonologists and Allergists
            • Physician Quotes on Nucala Sales Representative Frequency and Reach
          • Satisfaction with Nucala Sales Representatives
            • Nucala Representative Performance Rating by Allergists
            • Nucala Representative Performance Rating by Pulmonologists
            • Physician Quotes on Satisfaction with Nucala Sales Representatives
          • Nucala Message Recall
            • Nucala Representative Discussion Topics with Pulmonologists
            • Nucala Representative Discussion Topics with Allergists
            • Positioning of Nucala Against a Respiratory Biologic by Nucala Representative
            • Ideal Patient Type Suggestion by Nucala Representative to Physician
            • Ideal Patient Type Suggestions Made by Representative to Pulmonologists
            • Ideal Patient Type Suggestions Made by Representative to Allergists
            • Physician Quotes on Nucala Message Recall
        • Appendix
          • Asthma Patients on Chronic Drug Treatment, by Severity
          • Asthma Patients Successfully Controlled with Chronic Drug Treatment by Severity
          • Treatment Changes for Treatment-Naive Patients
          • Reasons for Switching Asthma Treatment
          • Patients on Each Step in the GINA Guidelines
          • Prescribing Rates of Xolair and Cinqair Among Pulmonologists and Allergists
          • Requirements in Nucala's Managed Care Approval Process
          • Eosinophil Levels Requirements for Managed Care Approval of Nucala Prescriptions
          • Step Therapy Requirements for Managed Care Approval of Nucala Prescribing
          • Market for Alternative Administration Routes for Nucala
          • Unaided Awareness of Products in Development for Asthma
          • Unaided Awareness of Products in Development for Asthma
          • Allergists's Familiarity with Products in Development for Asthma
          • Pulmonologists' Familiarity with Products in Development for Asthma
          • Final Comments from Physicians

      Author(s): Colleen E. Albacker, Ph.D.; Mohit Nasa, M.B.A.

      Colleen Albacker, Ph.D., is Head of Immune and Inflammation at Clarivate. She manages a team of analysts and managers generating syndicated market research content on respiratory, rheumatology, dermatology, and gastrointestinal indications. She has authored market research reports analyzing physician, payer, and market trends across various autoimmune indications. Previously, Dr. Albacker conducted her graduate research on chromatin-modifying factors in zebrafish cancer and hematopoietic development at Harvard Medical School and Boston Children’s Hospital. She also gained experience with market research through a fellowship with the Harvard Office of Technology Development. Dr. Albacker holds a Ph.D. in genetics from Harvard University and a B.S. in biology with honors from the Pennsylvania State University.

      Mohit Nasa, M.B.A., is a principal analyst on the Immune and Inflammatory Disorders team at Clarivate. He has authored content on such indications as systemic lupus erythropoiesis, psoriasis, asthma, and rheumatoid arthritis. Previously, he worked as a senior business analyst at Novartis, where he was responsible for end-to-end market assessment and related projects for Novartis’s asthma brand Xolair. Mr. Nasa holds a bachelor’s degree in pharmacy and an M.B.A. in marketing and CRM from Amity Business School in India.


      Related Reports

      Asthma | Disease Landscape and Forecast | G7 | 2020

      The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva), oral dr...

      View Details

      Asthma - Current Treatment - Detailed, Expanded Analysis (EU5)

      The asthma market in the EU5 is highly competitive. Ma...

      View Details

      Asthma - Landscape & Forecast - Disease Landscape & Forecast

      The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s...

      View Details